<DOC>
	<DOCNO>NCT00797511</DOCNO>
	<brief_summary>The present study design meet requirement Taiwanese Health Authorities registration ADACEL POLIO Taiwan . Subjects receive one dose study vaccine 6 8 year age . Blood sample take antibody titration . The expected total duration follow-up subject 28 day .</brief_summary>
	<brief_title>Immunogenicity Safety Adacel Polio Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 6 8 year day inclusion Informed consent form sign parent ( ) another legally acceptable representative Subject parent/guardian able attend schedule visit comply trial procedure Written documentation complete primary series fourth dose diphtheria , tetanus , pertussis ( DTP ) Polio vaccine Parent ( ) /legal representative present fully complete preinclusion medical questionnaire . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Known systemic hypersensitivity vaccine component ( residue carry manufacture , formaldehyde , glutaraldehyde , streptomycin , neomycin polymyxin B ) history lifethreatening reaction trial vaccine vaccine contain substance specific focus subject , previous administration DTP vaccine , one prelisted adverse event . Chronic illness , stage could interfere trial conduct completion , opinion investigator Progressive neurologic disorder , include infantile spasm , uncontrolled epilepsy , progressive encephalopathy Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccine 4 week precede trial vaccination Planned receipt vaccine 4 week follow trial vaccination Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B surface ( HBs ) antigen , Hepatitis C seropositivity History diphtheria and/or tetanus and/or pertussis and/or poliomyelitis infection ( confirm either clinically , serologically microbiologically ) Previous fifth vaccination diphtheria and/or tetanus and/or pertussis and/or poliomyelitis diseases either trial vaccine another vaccine Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate intramuscular ( IM ) vaccination Subject high risk diphtheria and/or tetanus and/or pertussis and/or poliomyelitis infection trial Received oral inject antibiotic therapy within 72 hour prior blood draw Febrile illness ( temperature ≥ 37.5°C ) moderate severe acute illness/infection day vaccination , accord investigator judgment</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Poliomyelitis</keyword>
</DOC>